Search the collection

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 1
ArticlesPeer ReviewedFull Text
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
Author / Creator:Lipsky, Peter E ; Calabrese, Leonard H ; Kavanaugh, Arthur ; Sundy, John S ; Wright, David ; Wolfson, Marsha ; Becker, Michael A
Publisher:England: BioMed Central Ltd
Journal title:Arthritis research & therapy, 2014-03, Vol.16 (2), p.R60-R60, Article R60
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 2
ArticlesPeer ReviewedFull Text
Pegloticase: In Treatment-Refractory Chronic Gout
Author / Creator:Lyseng-Williamson, Katherine A.
Publisher:Cham: Springer International Publishing
Journal title:Drugs (New York, N.Y.), 2011-11, Vol.71 (16), p.2179-2192
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 3
ArticlesPeer ReviewedFull Text
AB1070 Adverse events with short vs long-term pegloticase therapy in trials of refractory chronic gout
Author / Creator:Wolfson, M. ; Rehrig, C. ; Bahrt, K.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.699
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 4
ArticlesPeer ReviewedFull Text
AB1074 Understanding infusion reactions and their relationship to urate lowering in patients with refractory chronic gout (RCG): Pooled data from pegloticase trials
Author / Creator:Baraf, H. ; Yood, R. ; Sundy, J. ; Ottery, F. ; Becker, M.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.699
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 5
ArticlesPeer ReviewedFull Text
Pegloticase: a guide to its use in treatment-refractory chronic gout in the EU
Author / Creator:Lyseng-Williamson, Katherine A.
Publisher:Cham: Springer International Publishing AG
Journal title:Drugs & therapy perspectives : for rational drug selection and use, 2013-06, Vol.29 (6), p.155-160
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 6
ArticlesPeer ReviewedFull Text
Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
Author / Creator:Khanna, Puja P ; Nuki, George ; Bardin, Thomas ; Tausche, Anne-Kathrin ; Forsythe, Anna ; Goren, Amir ; Vietri, Jeffrey ; Khanna, Dinesh
Publisher:England: BioMed Central Ltd
Journal title:Health and quality of life outcomes, 2012-09, Vol.10 (1), p.117-117, Article 117
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 7
ArticlesPeer ReviewedFull Text
Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials
Author / Creator:Yood, Robert A ; Ottery, Faith D ; Irish, William ; Wolfson, Marsha
Publisher:England: BioMed Central
Journal title:BMC research notes, 2014-01, Vol.7 (1), p.54-54
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 8
ArticlesPeer ReviewedFull Text
Pegloticase and the patient with treatment-failure gout
Author / Creator:Dave, Amish J ; Kelly, Victoria M ; Krishnan, Eswar
Publisher:London: Taylor & Francis
Journal title:Expert review of clinical pharmacology, 2012-09, Vol.5 (5), p.501-508
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 9
Newsletter articlesFull Text
Horizon Pharma plc Presents Data on KRYSTEXXA® (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting: Data Demonstrate Patients Defined as "Non-Responders" Ac...
Publisher:New York: NASDAQ OMX Corporate Solutions, Inc
Journal title:NASDAQ OMX's News Release Distribution Channel, 2016
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 10
Newsletter articlesFull Text
New Data Demonstrate KRYSTEXXA-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
Publisher:NewsRX LLC
Journal title:Pharma Business Week, 2012, p.125
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 11
Newsletter articlesFull Text
Horizon Pharma plc Presents Data on KRYSTEXXA (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting
Publisher:Melbourne: News Bites Pty Ltd
Journal title:News Bites - Healthcare & Equipment, 2016
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 12
Newsletter articlesFull Text
Press Release: Horizon Pharma plc Presents Data on KRYSTEXXA(R) (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2016
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 13
ArticlesFull Text
Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
Publisher:NewsRX LLC
Journal title:NewsRx Health & Science, 2012-07, p.16
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 14
Newsletter articlesFull Text
Savient Announces Named Patient Programme for KRYSTEXXA in the European Union for Patients with Refractory Chronic Gout
Publisher:NewsRX LLC
Journal title:Politics & Government Week, 2012, p.88
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 15
Newsletter articlesFull Text
Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Publisher:NewsRX LLC
Journal title:Biotech Week, 2011, p.224
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 16
Newsletter articlesFull Text
New Data Demonstrate KRYSTEXXA(R)-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life: Post-Hoc Analyses Examining HRQOL, Tophus Reduction and In...
Publisher:New York: PR Newswire Association LLC
Journal title:PR Newswire, 2012
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 17
Newsletter articlesFull Text
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Publisher:NewsRX LLC
Journal title:Biotech Week, 2009, p.3707
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 18
Newsletter articlesFull Text
PRESS RELEASE: New Data Demonstrate KRYSTEXXA(R)-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2012
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 19
Newsletter articlesFull Text
Savient Pharmaceuticals: Krystexxa Phase III Data Demonstrates Improved Health-Related Quality of Life in Refractory Chronic Gout Patients
Publisher:Jacksonville: Close-Up Media, Inc
Journal title:Professional Services Close - Up, 2012
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 20
Newsletter articlesFull Text
Savient Pharmaceuticals: Krystexxa Phase III Data Demos Improved Health-Related Quality of Life in Refractory Chronic Gout Patients
Publisher:Jacksonville: Close-Up Media, Inc
Journal title:Health & Beauty Close - Up, 2012
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Showing 1 to 20 of 72 results

Export record to excel

Export this record

Export record to excel

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

Export this record

Export record to excel

Pegloticase: In Treatment-Refractory Chronic Gout

Export this record

Export record to excel

AB1070 Adverse events with short vs long-term pegloticase therapy in trials of refractory chronic gout

Export this record

Export record to excel

AB1074 Understanding infusion reactions and their relationship to urate lowering in patients with refractory chronic gout (RCG): Pooled data from pegloticase trials

Export this record

Export record to excel

Pegloticase: a guide to its use in treatment-refractory chronic gout in the EU

Export this record

Export record to excel

Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey

Export this record

Export record to excel

Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

Export this record

Export record to excel

Pegloticase and the patient with treatment-failure gout

Export this record

Export record to excel

Horizon Pharma plc Presents Data on KRYSTEXXA® (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting: Data Demonstrate Patients Defined as "Non-Responders" Ac...

Export this record

Export record to excel

New Data Demonstrate KRYSTEXXA-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life

Export this record

Export record to excel

Horizon Pharma plc Presents Data on KRYSTEXXA (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting

Export this record

Export record to excel

Press Release: Horizon Pharma plc Presents Data on KRYSTEXXA(R) (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting

Export this record

Export record to excel

Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients

Export this record

Export record to excel

Savient Announces Named Patient Programme for KRYSTEXXA in the European Union for Patients with Refractory Chronic Gout

Export this record

Export record to excel

Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients

Export this record

Export record to excel

New Data Demonstrate KRYSTEXXA(R)-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life: Post-Hoc Analyses Examining HRQOL, Tophus Reduction and In...

Export this record

Export record to excel

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout

Export this record

Export record to excel

PRESS RELEASE: New Data Demonstrate KRYSTEXXA(R)-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life

Export this record

Export record to excel

Savient Pharmaceuticals: Krystexxa Phase III Data Demonstrates Improved Health-Related Quality of Life in Refractory Chronic Gout Patients

Export this record

Export record to excel

Savient Pharmaceuticals: Krystexxa Phase III Data Demos Improved Health-Related Quality of Life in Refractory Chronic Gout Patients

Refine your search